Rigel Pharmaceuticals Inc (RIGL)
EBITDA Margin
33.97%
TTM · Period ending:
RIGL EBITDA Margin
Latest reported33.97%period ending
Latest reported33.97%period ending
RIGL TTM EBITDA Margin (-192.96% → 33.97%)
TTM ebitda margin
High-resolution chart · PNG
RIGL ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| 33.9722% | |
| 43.7943% | |
| 44.7061% | |
| 44.0764% | |
| 40.7971% | |
| 23.8594% | |
| 15.9038% | |
| 8.6795% | |
| -3.7797% | |
| -9.1229% | |
| -14.5283% | |
| -12.9382% | |
| -24.9487% | |
| -30.7462% | |
| -44.7997% | |
| -86.892% | |
| -89.4821% | |
| -93.3281% | |
| -7.5632% | |
| -6.0369% | |
| -2.0545% | |
| -5.4124% | |
| -25.4877% | |
| -24.4158% | |
| -21.7625% | |
| -26.2495% | |
| -111.1119% | |
| -56.8695% | |
| -89.3936% | |
| -112.5409% | |
| -160.608% | |
| -1,507.5466% | |
| -3,513.8817% | |
| -9,744% | |
| -1,765.1873% | |
| -917.8648% | |
| -654.534% | |
| -326.6607% | |
| -309.2283% | |
| -230.6906% | |
| -140.8977% | |
| -156.6843% | |
| -174.0924% | |
| -208.8786% | |
| -472.2521% | |
| -814.7871% | |
| -1,077.4545% | |
| -1,470.5913% | |
| -1,490.4348% | |
| -1,162.5734% | |
| -1,208.8811% | |
| -6,667.7143% | |
| -6,905.3571% | |
| -6,579.3333% | |
| -4,284.7556% | |
| -4,320.9778% | |
| -1,359.9243% | |
| -1,575.1273% | |
| -1,774.4632% | |
| 63.0802% | |
| 14.4181% | |
| -1,251.3646% | |
| 24.8827% | |
| -85.5222% | |
| -2,554.5749% | |
| -14,671.2% | |
| -1,519.525% | |
| -1,291.5625% | |
| -890.7593% | |
| -620.5% | |
| -966.9513% | |
| -483.847% | |
| -190.8772% | |
| -124.3659% | |
| -95.6139% | |
| -107.494% | |
| -189.4854% | |
| -282.8392% | |
| -442.1851% | |
| -595.3802% | |
| -905.8492% | |
| -1,151.3628% | |
| -897.8916% | |
| -641.111% | |
| -541.9391% | |
| -340.5699% | |
| -261.2222% | |
| -222.0861% | |
| -191.6414% | |
| -197.5678% | |
| -172.2357% | |
| -143.473% | |
| -136.2335% | |
| -118.9452% | |
| -358.5742% | |
| -319.7155% | |
| -242.2683% | |
| -192.9566% |